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Abstract
Background:  Transarterial chemoembolization (TACE) is a well accepted treatment for
inoperable hepatocellular carcinoma (HCC). While minor complications involve 10% of all patients,
severe complications are rare.
Case Presentation: We describe a case of a 90-year-old male with a large, superficial HCC who
underwent TACE. He had a significant intraperitoneal bleed secondary to tumor rupture
immediately following the procedure.
Conclusion: Tumor size and superficial location must be considered risk factors for tumor
rupture and related complications.
Introduction
Although operative resection is the preferred method of
treatment for hepatocellular carcinoma (HCC), only 20%
of patients are candidates for resection at the time of diag-
nosis [1,2]. As a result of its therapeutic successes, survival
advantage and minimally invasive technique, transarterial
chemoembolization (TACE) has become a well accepted
treatment for inoperable HCC [1,3,4]. While the specific
agents employed in TACE are varied, a reduction in
hepatic arterial blood supply to the tumor, as well as the
delivery of tumorcidal agents, remain the basic principles.
Numerous publications describe minor complications
associated with TACE in 10–12% of patients [2-8]. These
include postembolization syndrome (fever, abdominal
pain, nausea, and vomiting), impaired liver function, and
leukocytopenia [2,3,6]. While these are common, there
are very few reports of severe post-TACE complications in
the literature [6-8]. Major complications include a 3% rate
of irreversible liver failure, as well as liver abscess, upper
gastrointestinal bleeding, bile duct complications, acalcu-
lous cholecystitis, pulmonary embolism, spasm or occlu-
sion of hepatic artery and acute renal failure.
Case presentation
A 90-year-old male with a history of hypertension and
diabetes was incidentally diagnosed with a HCC. CT
described a large and hypervascular mass in the right
hepatic lobe (10 × 11 × 7 cm) in close proximity to the
liver capsule. His liver enzymes and function tests were
normal. He underwent transarterial chemoembolization
(TACE) with no intra-operative complications. The tumor
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was embolized with a combination of 50 mg of Cisplatin,
50 mg of Adriamycin and 20 mL of Lipidol. Within 4
hours of the procedure however, the patient became
hypotensive (systolic blood pressure = 90 mmHg), tachy-
cardic (heart rate = 156 beats per minute) and developed
a moderate abdominal tenderness. His hemoglobin
decreased from 141 to 92 g/L. The patient stabilized with
1.5 liters of crystalloid resuscitation. An urgent CT scan
revealed a large hemoperitoneum with no active arterial
contrast extravasation (Figures 1 &2). Scattered punctuate
foci of hyperattenuated particles located in the right para-
colic gutter suggested free intra-peritoneal chemoemboli-
zation agents. In spite of the ruptured HCC, the patient
underwent conservative management without a laparot-
omy. He required 2 units of packed red blood cells and 4
units of fresh frozen plasma after developing progressive
anemia, post-embolization syndrome and mild liver
impairment. He was also given intravenous antibiotics
(ceftraixone and flagyl). He recovered from his intra-
abdominal hemorrhage, but eventually died of ongoing
respiratory failure on post-TACE day 16.
Discussion
Our patient displayed a ruptured hepatocellular carci-
noma almost immediately after undergoing TACE. Rup-
ture, and its associated hemorrhage, represents a very rare
complication. The mechanism of bleeding is likely related
to necrosis of the liver capsule as a result of the chemoem-
bolization agents. The patient's ability to tolerate this
hemorrhage was likely limited by his age. There have only
been 5 cases reported in the literature [6,7]. As a collective,
these reports offer tumor size and superficial location as
possible risk factors for rupture. Four of five patients also
appeared to rupture in a relatively delayed timeframe (2 to
45 days post TACE). Only 1 patient, in addition to ours,
became symptomatic immediately after the procedure [6].
Furthermore, our patient was the only case who did not
undergo a laparotomy.
Conclusion
Although TACE is generally a safe procedure, intraperito-
neal bleeding due to tumor rupture must be considered a
potential complication when patients respond poorly
immediately after the procedure. As exemplified in our
patient, this appears especially important in large tumors
located adjacent to the liver capsule.
Patient family's perspective
"This beloved man was a caring person who's intellectual
abilities were entirely normal before the procedure. He
understood his disease and the treatment options offered
to him. At the time he was diagnosed, he was leading a
good life, was happy and enjoyed himself. He was com-
mitted to pursuing any and all options to fight the disease,
at any cost. Close family members had died from cancer
before him with basically no treatment and immense suf-
Computed tomographic scan of ruptured hepatocellular car- cinoma post-TACE Figure 1
Computed tomographic scan of ruptured hepatocel-
lular carcinoma post-TACE.
Computed tomographic scan of ruptured hepatocellular car- cinoma with associated hemorrhage immediately post-TACE Figure 2
Computed tomographic scan of ruptured hepatocel-
lular carcinoma with associated hemorrhage imme-
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fering. He was determined to go ahead with any treatment
that could help him live longer or relieve symptoms."
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